Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for...

Dr Tanuj Chawla and Dr Giovanni Selvaggi

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer ( Dr Tanuj Chawla and Dr Giovanni Selvaggi )

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and...

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

Kinetics of postop circulating cell-free DNA and impact on MRD detection rates...

Dr Stacey Cohen - Fred Hutchinson Cancer Center, Washington, USA

Kinetics of postop circulating cell-free DNA and impact on MRD detection rates in resected stage I-III colorectal cancer ( Dr Stacey Cohen - Fred Hutchinson Cancer Center, Washington, USA )

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not...

Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure ( Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK )

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful...

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )

The placebo effect in oncology trials and the criteria for approving drugs

Dr Bishal Gyawali - Queen's University, Kingston, Canada

The placebo effect in oncology trials and the criteria for approving drugs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Breast-conserving therapy may be option for multiple breast lesions

Dr Judy Boughey - Mayo Clinic, Rochester, USA

Breast-conserving therapy may be option for multiple breast lesions ( Dr Judy Boughey - Mayo Clinic, Rochester, USA )

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

ZUMA-7: Axi-cel is superior to standard of care across common prognostic...

Dr Fred Locke - Moffitt Cancer Center, Tampa, USA

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )

Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR...

Dr Fred Locke - Moffitt Cancer Center, Tampa, USA

Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR and OS in r/r LBCL patients ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...

Dr Ian Krop - Yale Cancer Center, Connecticut, USA

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )

ASH 2022: Multiple myeloma roundup

Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA

ASH 2022: Multiple myeloma roundup ( Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA )

More from ecancer